$MOS

S&P downgrades Mosaic outlook on high costs, weak cash flow

S&P Global Ratings downgraded Mosaic Co.’s outlook to negative from stable while keeping its BBB issuer credit rating. It expects funds from operations to debt below 20% in 2026. It projects adjusted EBITDA around $1.6B in 2026 vs $2.6B in 2025, citing high sulfur and ammonia costs, weaker phosphate margins, and negative discretionary cash flow of $400M to $500M.

Original reporting
Published Aug 6, 2026, 4:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefRegulation
Primary signal
$MOS
Bearish
medium confidence
Mentioned
$MOS
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$MOSBearishMed
01

Why it matters

The downgrade outlook is driven by expected funds from operations to debt falling below 20% in 2026, margin compression from high sulfur and ammonia costs, and a sustained discretionary cash flow deficit.

02

Market read

Credit outlook deterioration plus quantified cash flow and EBITDA expectations can influence equity risk premium and credit-spread pricing for MOS.

03

What to watch

The article emphasizes costs and demand deferral, but does not quantify potential hedging, inventory effects, or any offsetting operational actions beyond curtailed marginal production.

Relevance 7/10Novelty 6/10Timing: today, after-hours credit outlook change reported

Background

S&P Global Ratings affirmed Mosaic’s BBB issuer credit rating but revised the outlook to negative, focusing on 2026 leverage and cash flow deterioration.

Company-level read

Ticker impact

$MOSBearishMedium confidence
Context

S&P Global Ratings cut Mosaic’s outlook to negative, citing 2026 funds from operations to debt below 20% on high sulfur and ammonia costs.

Expected impact

Near-term downside bias as credit deterioration and weaker cash generation can pressure spreads, funding costs, and equity sentiment.

Evidence & confidence

The article provides specific credit-metric thresholds, EBITDA and cash flow deficit ranges, and cost drivers (sulfur/ammonia) that directly affect Mosaic’s ability to delever.

Market effects

Highlights fertilizer input-cost volatility (sulfur/ammonia) and how it can quickly translate into weaker cash flow and credit risk for phosphate producers.

Demand softness is linked to weak crop pricing and deferred purchases in North America and Brazil, which can weigh on regional shipment expectations.

References global sulfur supply concentration and Hormuz-related export disruptions, reinforcing that geopolitical supply shocks can propagate into fertilizer margins.

Counterpoint

If sulfur and ammonia prices mean-revert or phosphate pricing stabilizes, the cash flow deficit and credit metrics could improve faster than S&P’s base case.

Key entities

  • The Mosaic Co.

    Phosphate producer whose 2026 cash flow and leverage metrics are cited as weakening due to input-cost pressure.

  • S&P Global Ratings

    Revised Mosaic’s outlook to negative while affirming the BBB issuer credit rating.

Related articles

$MOSLow

MOSAIC CO (MOS): Results of Operations and Financial Condition

MOSAIC CO (MOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 performancedataq22026-ex992.htm EX-99.2 - PERFORMANCE DATA Document Exhibit 99.2 The Mosaic Company Selected Calendar Quarter Financial Information (Unaudited) Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Consolidated data (in millions, except per sha

$BAMed

scrutiny Archives

The FAA ordered inspections of hundreds of Boeing 737 MAX jets for possible fuselage cracks, according to the US Federal Aviation Administration. The move adds to ongoing regulatory and safety scrutiny of Boeing’s 737 MAX program, following prior controversies after twin crashes in 2018 killed 346 people.

$AMGNMed

Amgen (AMGN) Is Up 6.7% After EMA Backs Broader Repatha Use in High-Risk Patients – Has The Bull Case Changed?

Amgen (AMGN) shares rose about 6.7% after the EMA CHMP issued a positive opinion to expand Repatha’s use in Europe for adults with or at high risk for atherosclerotic cardiovascular disease, based on Phase 3 VESALIUS-CV results. If approved by the European Commission, it could widen the eligible patient pool. The article cites Q2 2026 revenue of $10,054 million and net income of $2,375 million.

$UNHMed

COMMENTARY: Trump administration finds a new way to punish Medicare members — Hiking their drug bills

The article says the Trump administration, led by Medicare chief Mehmet Oz, will end the Part D Premium Stabilization Demonstration subsidy for Medicare drug coverage on Dec. 31 instead of continuing through at least 2027. It cites GAO cost estimates of about $9.8B over two years and warns premiums for 23M enrollees could rise, including possible doubling for 11M.

$CMIMed

Locally-made Cummins engine to hit market in 2027

Cummins said the EPA clarified emissions requirements, allowing its locally made X15N engine to move into market deployment. The EPA rule scales back emissions warranty requirements and removes deratement, with added lead time for useful-life rules. Cummins plans limited 2027 X15 and X10 production in Jan 2027, full production in Q4 2027 and Q3 2027. Cummins raised 2026 revenue guidance to up 10% to 13%.

$DEOMed

India warned Diageo that its whisky’s ’matured in American oak casks’ claim was misleading

Reuters reports India’s food regulator FSSAI warned Diageo’s unit United Spirits that its Royal Challenge whisky label claiming “matured in American oak casks” was misleading, saying most of the product was not matured. FSSAI also banned some Diageo and Inbrew brands for artificial flavouring. Diageo said it is engaging FSSAI and expects no financial impact.